JP2021522266A5 - - Google Patents

Info

Publication number
JP2021522266A5
JP2021522266A5 JP2020560247A JP2020560247A JP2021522266A5 JP 2021522266 A5 JP2021522266 A5 JP 2021522266A5 JP 2020560247 A JP2020560247 A JP 2020560247A JP 2020560247 A JP2020560247 A JP 2020560247A JP 2021522266 A5 JP2021522266 A5 JP 2021522266A5
Authority
JP
Japan
Prior art keywords
abcb5
pip2
composition
cancer
isoform
Prior art date
Application number
JP2020560247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522266A (ja
JPWO2019210109A5 (https=
JP7611701B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/029235 external-priority patent/WO2019210109A1/en
Publication of JP2021522266A publication Critical patent/JP2021522266A/ja
Publication of JP2021522266A5 publication Critical patent/JP2021522266A5/ja
Publication of JPWO2019210109A5 publication Critical patent/JPWO2019210109A5/ja
Priority to JP2024061950A priority Critical patent/JP2024154382A/ja
Application granted granted Critical
Publication of JP7611701B2 publication Critical patent/JP7611701B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560247A 2018-04-25 2019-04-25 Ａｂｃｂ５のリガンドおよび基質 Active JP7611701B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024061950A JP2024154382A (ja) 2018-04-25 2024-04-08 Ａｂｃｂ５のリガンドおよび基質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662670P 2018-04-25 2018-04-25
US62/662,670 2018-04-25
PCT/US2019/029235 WO2019210109A1 (en) 2018-04-25 2019-04-25 Abcb5 ligands and substrates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024061950A Division JP2024154382A (ja) 2018-04-25 2024-04-08 Ａｂｃｂ５のリガンドおよび基質

Publications (4)

Publication Number Publication Date
JP2021522266A JP2021522266A (ja) 2021-08-30
JP2021522266A5 true JP2021522266A5 (https=) 2022-05-09
JPWO2019210109A5 JPWO2019210109A5 (https=) 2022-05-09
JP7611701B2 JP7611701B2 (ja) 2025-01-10

Family

ID=68295729

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560247A Active JP7611701B2 (ja) 2018-04-25 2019-04-25 Ａｂｃｂ５のリガンドおよび基質
JP2024061950A Pending JP2024154382A (ja) 2018-04-25 2024-04-08 Ａｂｃｂ５のリガンドおよび基質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024061950A Pending JP2024154382A (ja) 2018-04-25 2024-04-08 Ａｂｃｂ５のリガンドおよび基質

Country Status (10)

Country Link
US (1) US12448461B2 (https=)
EP (1) EP3784249A4 (https=)
JP (2) JP7611701B2 (https=)
KR (2) KR102928177B1 (https=)
CN (1) CN112423765A (https=)
AU (2) AU2019257728A1 (https=)
CA (1) CA3097875A1 (https=)
MX (1) MX2020011297A (https=)
SG (1) SG11202010260XA (https=)
WO (1) WO2019210109A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2772535T1 (sl) 2006-05-31 2022-08-31 Children's Medical Center Corporation ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
AU2014262590B2 (en) 2013-05-10 2018-05-10 Children's Medical Center Corporation Wound healing and tissue engineering
CN111007240A (zh) * 2019-12-02 2020-04-14 中国医学科学院北京协和医院 一种基于crispr技术的均相酶免疫检验系统及其方法和应用
CN115835882A (zh) * 2020-04-15 2023-03-21 儿童医学中心公司 靶向多形性胶质母细胞瘤中的abcb5
CN113082210B (zh) * 2021-03-09 2023-04-18 广州白云山医药集团股份有限公司白云山制药总厂 一种肿瘤化疗药物组合物
CN116445573A (zh) * 2022-08-30 2023-07-18 苏州大学 一种以抑制trim54泛素化降解stat2为靶点的抗病毒ade药物筛选方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3587465T2 (de) 1984-09-10 1994-01-20 Hsc Res Dev Corp Vielfache Drogen-Resistenz in Säugetierzellinien und Isolierung der determinanten Glykoprotein-DNS.
US5837258A (en) 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
ES2329953T3 (es) 1996-04-19 2009-12-02 Osiris Therapeutics, Inc. Regeneracion e incremento de hueso utilizando celulas madre mesenquimales.
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
AU749675B2 (en) 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
CA2266805C (en) 1998-03-27 2015-04-28 An-Go-Gen Inc. Cell-based gene therapy in the treatment of pulmonary disorders
AU2999199A (en) 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
PT1082410E (pt) 1998-05-29 2007-11-09 Osiris Therapeutics Inc Células estaminais mesenquimatosas humanas cd45+ e/ou fibroblastos+
JP2003510071A (ja) 1999-09-28 2003-03-18 ジェンテスト・コーポレーション Ｐ−糖タンパク質およびその使用
US6673606B1 (en) 2000-04-12 2004-01-06 The Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells
CA2411101C (en) 2000-06-05 2018-01-16 Brigham And Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
US20040175366A1 (en) 2003-03-07 2004-09-09 Acell, Inc. Scaffold for cell growth and differentiation
EP1702061A4 (en) 2003-11-24 2007-05-02 Univ Rockefeller METHOD OF INSULATING A SELF-RENEWING, MULTIPOTENTIAL, SLOWLY CIRCULATING CELL
US20050186672A1 (en) 2004-01-27 2005-08-25 Reliance Life Sciences Pvt. Ltd. Tissue system with undifferentiated stem cells derived from corneal limbus
WO2006103685A2 (en) 2005-03-28 2006-10-05 Vision Research Foundation A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue
KR101441843B1 (ko) 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
WO2007112097A2 (en) 2006-03-24 2007-10-04 Children's Medical Center Corporation Novel signature self renewal gene expression programs
GB0610778D0 (en) 2006-05-31 2006-07-12 Het Nl Kanker I Phosphatidylinositol phospahte and apoptosis
SI2772535T1 (sl) 2006-05-31 2022-08-31 Children's Medical Center Corporation ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji
WO2008013492A1 (en) 2006-07-28 2008-01-31 Chundsell Medicals Ab Embryonic stem cell markers for cancer diagnosis and prognosis
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2155248B1 (en) 2007-04-12 2015-06-10 The Brigham and Women's Hospital, Inc. Targeting abcb5 for cancer therapy
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
EP3978928A1 (en) 2008-11-14 2022-04-06 The Brigham and Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2010065711A1 (en) * 2008-12-04 2010-06-10 Adimab, Inc. An abcb5 epitope and antibodies thereto for the treatment of cancer
KR101138091B1 (ko) 2011-08-31 2012-04-24 세원셀론텍(주) 중간엽 줄기세포 기본 배양 배지 조성방법, 중간엽 줄기세포 기본 배양 배지 및 이를 이용하여 배양분화된 세포치료제
WO2014130518A1 (en) 2013-02-19 2014-08-28 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
AU2014262590B2 (en) 2013-05-10 2018-05-10 Children's Medical Center Corporation Wound healing and tissue engineering
WO2016179576A1 (en) * 2015-05-07 2016-11-10 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
WO2016184793A1 (en) * 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
ES2905558T3 (es) 2015-11-13 2022-04-11 Avellino Lab Usa Inc Procedimientos para el tratamiento de las distrofias corneales
WO2018185584A1 (en) 2017-04-05 2018-10-11 Pluristem Ltd. Methods and compositions for treating acute lung injury and respiratory distress syndrome
US20220184136A1 (en) 2019-03-28 2022-06-16 Children's Medical Center Corporation Highly functional manufactured abcb5+ mesenchymal stem cells
AU2020368845A1 (en) 2019-10-18 2022-05-12 Amniotics Ab Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
EP4125960A4 (en) 2020-03-30 2024-04-03 Children's Medical Center Corporation USING STEM CELLS TO TREAT EXCESSIVE INFLAMMATION
CN115835882A (zh) 2020-04-15 2023-03-21 儿童医学中心公司 靶向多形性胶质母细胞瘤中的abcb5
AU2021262864A1 (en) 2020-04-30 2022-11-17 Children's Medical Center Corporation Antibodies specific to ABCB5 and uses thereof

Similar Documents

Publication Publication Date Title
JP2021522266A5 (https=)
Yamanishi et al. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis
ES2585702T3 (es) Composiciones y métodos para la unión al ácido lisofosfatídico
Kleinbongard et al. TNFα in myocardial ischemia/reperfusion, remodeling and heart failure
Waldner et al. Interleukin-6-a key regulator of colorectal cancer development
JP2022521454A (ja) 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法
ES2983967T3 (es) Modelos de roedores de enfermedad DITRA y usos de estos
KR101436578B1 (ko) 척추 측만증의 발병 위험성을 측정하는 방법, 척추 측만증에 걸린 대상자를 계층화하는 방법, 척추 측만증에 걸린 대상자에 있어서 고정기의 효능을 평가하는 방법, 및 이를 위한 키트
US9254309B2 (en) Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
US8765797B2 (en) TG2 inhibitors and uses thereof
Patel et al. Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1
JP7107839B2 (ja) Ｐｋｍ２モジュレーター及びｈｍｇｂ１の組合せ製剤
Ditiatkovski et al. An apolipoprotein AI mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice
Collins-Hooper et al. Propeptide-mediated inhibition of myostatin increases muscle mass through inhibiting proteolytic pathways in aged mice
Kim et al. Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist
KR20220025713A (ko) 유전성 신경병증 및 연관 장애의 치료 및 검출
Murmu et al. RETRACTED: Dynamic antagonism between RNA-binding protein CUGBP2 and cyclooxygenase-2-mediated prostaglandin E2 in radiation damage
WO2016176617A2 (en) Method for treating high-grade gliomas
JP5891173B2 (ja) がん幹細胞を含むまたはそれに由来するがんの治療、予防および診断のための方法および組成物
Carlson et al. fMLP induces Hsp27 expression, attenuates NF-κB activation, and confers intestinal epithelial cell protection
JPWO2019210109A5 (https=)
Tada et al. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma
US11419894B2 (en) Modified natural killer cells for the treatment of cancer
ES2861516T3 (es) Oligonucleótidos antisentido para IL-34 y métodos de uso de los mismos
WO2020219926A1 (en) Treatment of cancer with cdk inhibitors